ArticleCell biochemistry and biophysics2026
Oxiracetam Improves Cognitive Disorder in AD by Modulating AMPAR Subunits GluA1/GluA2 Kinetics.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundOxiracetam (ORC) is a commonly used nootropic drug in clinical practice. Alzheimer’s disease (AD) is the primary cause of cognitive decline and loss of independence in the elderly. Currently, the mechanism by which ORC ameliorates AD-related cognitive impairment remains unclear. This study explored its therapeutic potential and underlying mechanisms.
methodsAmyloid precursor protein/presenilin 1 (APP/PS1) double transgenic AD model mice and C57BL/6 control mice were utilized, with a comprehensive methodology employed that spanned behavioral assessments, histopathological examinations, molecular biological methods, omics analyses, and electrophysiological evaluations.
resultsBehavioral tests on APP/PS1 transgenic mice showed that ORC significantly improved cognitive function. HE staining and immunohistochemistry revealed that ORC reduced neurodegeneration in the hippocampal CA1 region of mice. Compared with the wild-type (WT) control group, the concentrations of NeuN, GAP43, MAP2, and Syn proteins in the hippocampus of APP/PS1 mice were significantly decreased, and ORC intervention reversed this decline. Proteomic and transcriptomic analyses suggested that ORC could regulate the glutamate receptor pathway. Electrophysiological studies found that ORC significantly enhanced the reactivity of Hippocampus neurons and increased the frequency and amplitude of sEPSCs, AMPAR-dependent eEPSCs, and mEPSCs. Kinetics studies showed that ORC slowed down the desensitization rate of GluA1 and GluA2 subunits of AMPAR, had no significant effect on their inactivation, and promoted the recovery of GluA2 subunit-desensitized receptors with no effect on GluA1.
conclusionsORC may improve AD-related cognitive impairment through the aforementioned regulation of AMPAR subunit functions, providing theoretical and experimental basis for the analysis of central nervous system drugs and the exploration of new therapeutic targets for AD.
Indexed as
Identifiers
41739317What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.